BioCentury
ARTICLE | Clinical News

Neurocrine starts insomnia Phase III

November 16, 2001 8:00 AM UTC

NBIX began its first Phase III trial of NBI-34060 GABA(A) receptor agonist to treat chronic insomnia. The double-blind study is expected to enroll 500 patients in the U.S. and Europe, and will evaluat...